Trial Profile
A Study to Evaluate the Efficacy, Safety and Tolerability of Triple Therapy with Peginterferon Plus Ribavirin Plus either Telaprevir or Boceprevir in Chronic Hepatitis C Virus (HCV) Infected Patients with Minimal versus Advanced Fibrosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Dec 2015
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon (Primary) ; Ribavirin (Primary) ; Telaprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 16 Dec 2015 New trial record